Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc.（GLUE）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · GLUE · 截至 2025年3月31日
股东结构概览
108
机构持有人数
$276.19M
机构持仓总市值
▼ $147.07M vs Q4
65.12M
总流通股
freeFloat 64.71%
59.52M
13F 申报持股数
▼ 1.46M vs Q4
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
GLUE 最大股东 · 机构持仓
Q1 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
NEA MANAGEMENT COMPANY, LLC biological products, (no diagnostic substances) | 7.69M | 9.36% | 9.36% | $35.69B | May 14, 2025 | — held |
PRICE T ROWE ASSOCIATES INC /MD/ biological products, (no diagnostic substances) | 6.64M | 8.09% | 8.09% | $30.83B | May 14, 2025 | ▼ 472.5K |
BVF INC/IL biological products, (no diagnostic substances) | 5.66M | 6.89% | 6.89% | $26.26B | May 15, 2025 | ▲ 2.90M |
VERSANT VENTURE MANAGEMENT, LLC biological products, (no diagnostic substances) | 5.65M | 6.88% | 6.88% | $26.23B | May 7, 2025 | — held |
BAKER BROS. ADVISORS LP biological products, (no diagnostic substances) | 4.92M | 5.98% | 5.98% | $22.81B | May 15, 2025 | — held |
FMR LLC biological products, (no diagnostic substances) | 4.67M | 5.69% | 5.69% | $21.69B | May 12, 2025 | ▼ 874.3K |
AVORO CAPITAL ADVISORS LLC biological products, (no diagnostic substances) | 4.65M | 5.66% | 5.66% | $21.56B | May 15, 2025 | ▲ 300.5K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 3.77M | 4.59% | 4.59% | $17.48B | May 2, 2025 | ▼ 73.5K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 3.10M | 3.77% | 3.77% | $14.38B | May 9, 2025 | ▼ 56.3K |
SUVRETTA CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 1.56M | 1.90% | 1.90% | $7.26B | May 15, 2025 | — held |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q1 2025 对比上季度
Q1 2025
13
增持
+4.39M 股6
新建仓
首次建仓23
减持
−4.48M 股0
清仓
完全退出净股数变化（前50家）
83.2K
+4.39M / −4.48M
净新增持仓人
-4
新建 6 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
GLUE 内幕交易记录
数据来源：SEC Form 4
近期内部人员以卖出为主。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
6
买入笔数
13
卖出笔数
0.46
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Warmuth Markus President & CEO | Jun 1, 2026 | Sale | 4,998 | $19.41 | $97.0K | 595.0K | Form 4 ↗ |
Warmuth Markus President & CEO | Jun 1, 2026 | Sale | 468 | $19.73 | $9.2K | 594.5K | Form 4 ↗ |
Townson Sharon Chief Scientific Officer | May 29, 2026 | Sale | 6,000 | $19.87 | $119.2K | 67.8K | Form 4 ↗ |
Champoux Jennifer Chief Operating Officer | May 27, 2026 | Sale | 2,175 | $20.00 | $43.5K | 62.4K | Form 4 ↗ |
Champoux Jennifer Chief Operating Officer | May 22, 2026 | Sale | 2,176 | $19.00 | $41.3K | 62.4K | Form 4 ↗ |
Manning Anthony M. director | May 21, 2026 | Sale | 10,000 | $18.01 | $180.1K | 0 | Form 4 ↗ |
Warmuth Markus President & CEO | May 1, 2026 | Sale | 5,467 | $18.92 | $103.4K | 600.0K | Form 4 ↗ |
Warmuth Markus President & CEO | Apr 14, 2026 | Sale | 8,000 | $17.64 | $141.1K | 605.5K | Form 4 ↗ |
Nickson Philip Chief Business & Legal Officer | Apr 9, 2026 | Sale | 5,845 | $17.69 | $103.4K | 55.0K | Form 4 ↗ |
Bowen Matthew Principal Accounting Officer | Apr 6, 2026 | Award | 4,300 | — | — | 25.9K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Monte Rosa Therapeutics, Inc.（GLUE）主要由机构投资者持有，机构持股比例约为 91.4%。公司内部人员持股约 35.29%，散户及公众持股约占剩余的 0.00%。
Monte Rosa Therapeutics, Inc. 最大机构股东为 NEA MANAGEMENT COMPANY, LLC，截至 March 31, 2025 持有约 7.69 million 股，占总流通股的 9.36%。
目前共有 108 家机构持有 GLUE 股票，合计持仓市值约 $276,191,728，数据来源为最新 SEC 13F 申报。
常见问题
GLUE ownershipMonte Rosa Therapeutics, Inc.（GLUE）主要由机构投资者持有，机构持股约 91.4%。最大股东为 NEA MANAGEMENT COMPANY, LLC，持股比例 9.36%。内部人员持股约 35.29%。数据来源 SEC Form 13F，截至 March 31, 2025。